If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.Revenues came to $11.2bn, down 6% year-on-year on a constant currency basis. Non-GAAP earnings per share ("EPS") came to $1.80, and GAAP EPS $1.20, compared to $(4.40) and ...

Bristol Myers Squibb (BMY) reported $11.2 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 5.6%. EPS of $1.80 for the same period compares to -$4.40 a year ago.The reported revenue represents a surprise of +4.38% over the Zacks Consensus Estimate of $10.73 billion. With the consensus EPS estimate being $1.51, the EPS surprise was +19.21%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wal ...

Q1 2025 Results April 24, 2025 Not for Product Promotional Use Forward Looking Statements and Non-GAAP Financial Information This presentation contains statements about Bristol-Myers Squibb Company's (the "Company") future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. All statements that are ...

Financial Performance - Bristol Myers Squibb reported quarterly earnings of $1.80 per share, exceeding the Zacks Consensus Estimate of $1.51 per share, compared to a loss of $4.40 per share a year ago, representing an earnings surprise of 19.21% [1] - The company posted revenues of $11.2 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.38%, although this is a decrease from year-ago revenues of $11.87 billion [2] - Over the last four quarters, Bristol Myers has consistently surpassed consensus EPS estimates and revenue estimates [2] Stock Performance and Outlook - Bristol Myers shares have declined approximately 14.2% since the beginning of the year, while the S&P 500 has decreased by 8.6% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the sustainability of the recent earnings numbers [3][4] - The current consensus EPS estimate for the upcoming quarter is $1.69 on revenues of $11.35 billion, and for the current fiscal year, it is $6.76 on revenues of $45.82 billion [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Bristol Myers belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Exhibit 99.1 Bristol Myers Squibb Reports First Quarter Financial Results for 2025 Results Reflect Continued Growth Portfolio Momentum and Disciplined Execution (PRINCETON, N.J., April 24, 2025) – Bristol Myers Squibb (NYSE: BMY) today reports results for the first quarter of 2025. "Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squ ...

FILE PHOTO: The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, on Dec. 27, 2023.Bristol Myers Squibb on Thursday beat first-quarter estimates and hiked its revenue and profit guidance for the year, as the drugmaker cuts costs.The company now expects 2025 revenue to come in between $45.8 billion and $46.8 billion, up from a previous outlook of around $45.5 billion. Bristol Myers also expects full-year adjusted earnings of $6.70 to $7 per share, which c ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style ...

Core Viewpoint - Bristol Myers Squibb (BMY) is expected to report a significant increase in quarterly earnings per share, while revenues are projected to decline year-over-year [1]. Financial Projections - Analysts predict quarterly earnings of $1.54 per share, reflecting a 135% increase compared to the same period last year [1]. - Revenues are forecasted to be $10.74 billion, representing a year-over-year decrease of 9.5% [1]. - The consensus EPS estimate has been adjusted upward by 0.8% over the past 30 days, indicating a reassessment of initial projections by analysts [2]. Key Metrics Estimates - Net Sales for Recent LOE Products - Revlimid is estimated at $879.35 million, indicating a change of -47.3% from the prior-year quarter [5]. - Net Sales for In-Line Products - Opdivo is expected to reach $2.18 billion, reflecting a year-over-year change of +4.9% [5]. - Net Sales for Recent LOE Products - Abraxane is projected at $127.62 million, showing a change of -41.2% from the year-ago quarter [6]. - Net Sales for New Product Portfolio - Reblozyl is estimated at $483.40 million, indicating a change of +36.6% year-over-year [6]. - Net Sales for Recent LOE Products - Abraxane (U.S.) is expected to be $66.33 million, reflecting a year-over-year change of -54.3% [7]. - Net Sales for In-Line Products - Opdivo (U.S.) is projected at $1.19 billion, indicating a year-over-year change of +3.4% [7]. - Net Sales for In-Line Products - Pomalyst/Imnovid (U.S.) is expected to reach $582.15 million, reflecting a change of -2.5% from the prior-year quarter [8]. - Net Sales for Recent LOE Products - Revlimid (U.S.) is estimated at $706.32 million, indicating a change of -51.4% from the prior-year quarter [9]. - Net Sales for New Product Portfolio - Reblozyl (U.S.) is projected at $392.41 million, reflecting a change of +33.9% from the prior-year quarter [10]. Market Performance - Over the past month, Bristol Myers shares have recorded returns of -18.5%, compared to the Zacks S&P 500 composite's -6.9% change [10]. - Based on its Zacks Rank 3 (Hold), BMY is expected to perform in line with the overall market in the upcoming period [10].

Biotech giant Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2025 results on April 24, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $10.74 billion and $1.54 per share, respectively.Earnings estimate for 2025 has increased to $6.78 from $6.75 per share over the past 30 days, while that for 2026 has decreased to $6.06 from $6.08. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)Image Source: Zacks Investment ResearchBMY’s ...

Gilead Sciences, Inc. (GILD) and Bristol Myers Squibb (BMY) are leading biotechnology companies with broad and diverse portfolios and a global footprint.Gilead Sciences is a pioneer in developing treatments for human immunodeficiency virus (HIV). The company’s wide portfolio also includes drugs for liver, hematology/oncology and inflammation/respiratory diseases.On the other hand, Bristo Myers is focused on discovering, developing and delivering transformational drugs for oncology, hematology, immunology, c ...